Articles related to CONJUNCTIVITIS
Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitis
Aldeyra’s reproxalap shows considerable promise as a breakthrough treatment for ocular surface inflammatory conditions, highlighting its potential in addressing a significant unmet need in the field of optometry. Explore these groundbreaking clinical trial results.
Optometry June 26th 2023